8.60

1.04% -0.09

After Hours: 8.60

4 D Molecular Therapeutics Inc (FDMT)

Overview News Price History Option Chain Financials Discussions Forecast

4 D Molecular Therapeutics Inc stock is traded at $8.60, with a volume of 503.99K. It is down -1.04% in the last 24 hours and down -12.24% over the past month. 4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

Previous Close:

$8.69

Open:

$8.68

24h Volume:

503.99K

Relative Volume:

0.69

Market Cap:

$449.58M

Revenue:

$85.21M

Net Income/Loss:

$-140.11M

P/E Ratio:

-3.42

EPS:

-2.5146

Net Cash Flow:

$-109.62M

1W Performance:

-6.01%

1M Performance:

-12.24%

6M Performance:

-20.66%

1Y Performance:

+138.89%

1-Day Range:

$8.55

$8.90

1-Week Range:

$8.07

$9.35

52-Week Range:

$3.365

$12.34

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name

4 D Molecular Therapeutics Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

(510) 505-2680

Address

5858 HORTON STREET #455, EMERYVILLE

Employee

196

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

FDMT's Discussions on Twitter

Compare FDMT vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FDMT 4 D Molecular Therapeutics Inc	8.60	454.28M	85.21M	-140.11M	-109.62M	-2.5146
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Resumed	Barclays	Overweight
Nov-07-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jan-13-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
Nov-21-24	Initiated	Morgan Stanley	Underweight
Sep-23-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-15-24	Initiated	Barclays	Overweight
Feb-07-24	Resumed	Goldman	Buy
Oct-26-23	Initiated	RBC Capital Mkts	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Chardan Capital Markets	Buy
Jan-30-23	Initiated	BMO Capital Markets	Outperform
Nov-18-22	Initiated	H.C. Wainwright	Buy
Nov-15-22	Upgrade	Goldman	Neutral → Buy
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-22-22	Initiated	Jefferies	Buy
Jan-04-22	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	BofA Securities	Buy
Jan-05-21	Initiated	Evercore ISI	Outperform
Jan-05-21	Initiated	Goldman	Neutral

View All

4 D Molecular Therapeutics Inc Stock (FDMT) Latest News

May 20, 2026

Pittsburgh Post-Gazette - FinancialContent

May 20, 2026

4D Molecular Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus

May 20, 2026